Company Analysis
Sign in

Ligand Pharmaceuticals Incorporated (LGND)

Nasdaq: LGND · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 1994
Full chart Alerts Compare
Grade6.3
◀ Past 5.7● Present 6.9▶ Future 6.0
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$268M+60.4%
Net income$124M+3186.6%
Earnings per share$6.13+2886.4%
Operating cash flow$49.4M-49.1%
Cash$175M+141.9%
Debtn/a
Shareholders’ equity$1.02B+22.5%
Shares, diluted20.3M+11.0%
Return on equity12.2%
The recordfrom its filings
Filings in 2026110
Newest filingNov 12 · 144
Annual reportFeb 27, 2026
Quarterly reportOct 30, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$35.7M
Insider buys, 12 months$0.00
Patents granted761
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $254MNet income $51.5MCash from operations $91.0Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 6, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton LGND · research, not advice